Answers are grounded in this paper and cite their sources.
Here, we present the longest observation to date of patients with aMCC receiving first-line anti-programmed cell death-1 therapy. Pembrolizumab demonstrated durable tumor control, a generally manageable safety profile, and favorable OS compared with historical data from patients treated with first-line chemotherapy.
No takes yet. Share an insight, caveat, or question.
Nghiem et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: